Pellino 3 promotes the colitis‐associated colorectal cancer through suppression of IRF4 ‐mediated negative regulation of TLR4 signalling
Molecular Oncology · 2023-11 · 17 (11) · 2380-2395
DOI: 10.1002/1878-0261.13475 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 27.06.2023. Verfasst von Young-Mi Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Lee Gil Ya Cancer and Diabetes Institute, Gachon University College of Medicine, Incheon, Korea. Hauptthemen laut MEDLINE: Colitis-Associated Neoplasms, Toll-Like Receptor 4. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
The incidence of colitis‐associated colorectal cancer (CAC) has increased due to a high‐nutrient diet, increased environmental stimuli and inherited gene mutations. To adequately treat CAC, drugs should be developed by identifying novel therapeutic targets. E3 ubiquitin‐protein ligase pellino homolog 3 (pellino 3; Peli3) is a RING‐type E3 ubiquitin ligase involved in inflammatory signalling; however, its role in the development and progression of CAC has not been elucidated. In this study, we studied Peli3 ‐deficient mice in an azoxymethane/dextran sulphate sodium‐induced CAC model. We observed that Peli3 promotes colorectal carcinogenesis with increased tumour burden and oncogenic signalling pathways. Ablation of Peli3 reduced inflammatory signalling activation at the early stage of carcinogenesis. Mechanistic studies indicate that Peli3 enhances toll‐like receptor 4 (TLR4)‐mediated inflammation through ubiquitination‐dependent degradation of interferon regulatory factor 4, a negative regulator of TLR4 in macrophages. Our study suggests an important molecular link between Peli3 and colonic inflammation‐mediated carcinogenesis. Furthermore, Peli3 can be a therapeutic target in the prevention and treatment of CAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Lee Gil Ya Cancer and Diabetes Institute, Gachon University College of Medicine, Incheon, Korea.
- GILO Institute, GILO Foundation, Seoul, Korea.
- Medpacto Inc., Seoul, Korea.
ORCID-Profile: Seong-Jin Kim, Suntaek Hong
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, Y. M., Kim, H. Y., Ha Thi, H. T., Kim, J., Lee, Y. J., Kim, S. J., & Hong, S. (2023). Pellino 3 promotes the colitis‐associated colorectal cancer through suppression of IRF4 ‐mediated negative regulation of TLR4 signalling. Molecular Oncology, 17(11), 2380-2395. https://doi.org/10.1002/1878-0261.13475
Vancouver
Kim YM, Kim HY, Ha Thi HT, Kim J, Lee YJ, Kim SJ, et al. Pellino 3 promotes the colitis‐associated colorectal cancer through suppression of IRF4 ‐mediated negative regulation of TLR4 signalling. Molecular Oncology. 2023;17(11):2380-2395. doi:10.1002/1878-0261.13475
BibTeX
@article{Kim2023,
author = {Kim, Young-Mi and Kim, Hye-Youn and Ha Thi, Huyen Trang and Kim, Jooyoung and Lee, Young Jae and Kim, Seong-Jin and Hong, Suntaek},
title = {Pellino 3 promotes the colitis‐associated colorectal cancer through suppression of IRF4 ‐mediated negative regulation of TLR4 signalling},
journal = {Molecular Oncology},
year = {2023},
volume = {17},
number = {11},
pages = {2380--2395},
doi = {10.1002/1878-0261.13475}
}
EUVIMED